NeuroSense Therapeutics Ltd. (NRSN)
- Previous Close
1.3500 - Open
1.3600 - Bid 1.3000 x 100
- Ask 1.4000 x 100
- Day's Range
1.3001 - 1.3744 - 52 Week Range
0.4000 - 2.3300 - Volume
79,269 - Avg. Volume
314,582 - Market Cap (intraday)
23.574M - Beta (5Y Monthly) 1.56
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8300 - Earnings Date May 25, 2024 - May 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.25
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
www.neurosense-tx.comRecent News: NRSN
Performance Overview: NRSN
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NRSN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NRSN
Valuation Measures
Market Cap
23.57M
Enterprise Value
21.08M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.89
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-152.74%
Return on Equity (ttm)
-602.40%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-11.28M
Diluted EPS (ttm)
-0.8300
Balance Sheet and Cash Flow
Total Cash (mrq)
2.64M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.71M